

## Prof. Adnan AYDINER

### Personal Information

**Email:** aaydiner@istanbul.edu.tr

**Web:** <http://aves.istanbul.edu.tr/905/>

**Address:** İstanbul Üniversitesi İstanbul Tıp Fakültesi Çapa Fatih İstanbul

### International Researcher IDs

ORCID: 0000-0002-1104-5840

Publons / Web Of Science ResearcherID: AAU-4591-2020

Yoksis Researcher ID: 100819

### Research Areas

Oncology

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group**  
Gurbuz M., Kutlu Y., AKKUŞ E., KÖKSOY E. B., Kose N., Oven B. B., Uluc B. O., Demiray A. G., Erdem D., Demir B., et al.  
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.148, no.12, pp.3547-3555, 2022 (SCI-Expanded)
- II. **Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study**  
PAKSOY N., KHANMAMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., AYDINER A.  
Medicine (United States), vol.101, no.45, 2022 (SCI-Expanded)
- III. **The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)**  
Hizal M., Bilgin B., Paksoy N., Atci M. M., KAHRAMAN S., Kilickap S., Guven D. C., KESKİNKILIÇ M., Ayhan M., Eren O., et al.  
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022 (SCI-Expanded)
- IV. **Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC**  
DOĞAN İ., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., DEMİRKAZIK A., Aydiner A.  
MEDICINE, vol.101, no.34, 2022 (SCI-Expanded)
- V. **Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study**  
Hizal M., Bilgin B., Paksoy N., Kilickap S., Atci M. M., KAHRAMAN S., KESKİNKILIÇ M., Bilgetekin I., Ayhan M., Tural D., et al.  
FUTURE ONCOLOGY, vol.18, pp.2573-2582, 2022 (SCI-Expanded)
- VI. **Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.**  
Dogan I., Paksoy N., Ak N., Vatansever S., Saip P., Aydiner A.  
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16, 2022 (SCI-Expanded)
- VII. **The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study**

Hizal M., Bilgin B., Paksoy N., Acikgoz O., Sezer A., Gurbuz M., Ak N., Yucel S., Ayhan M., EROL C., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.148, no.6, pp.1501-1508, 2022 (SCI-Expanded)

- VIII. **Recurrent autoimmune encephalitis related to immune checkpoint inhibitors**  
Ser M. H., Samanci N. S., Naziye A. K., Aydiner A., Ozkara C.  
EPILEPTIC DISORDERS, vol.24, no.3, pp.609-613, 2022 (SCI-Expanded)
- IX. **Are false-negative rates of sentinel lymph node biopsy after neoadjuvant chemotherapy really associated with poor prognosis in clinically node-positive disease at diagnosis?**  
Cabioglu N., Karanlik H., Igci A., Muslumanoglu M., Tukenmez M., Emiroglu S., Ozkurt E., Yildirim N., Ilgun S., Onder S., et al.  
ANNALS OF SURGICAL ONCOLOGY, vol.29, no.SUPPL 1, pp.310-311, 2022 (SCI-Expanded)
- X. **Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study**  
Cil I., Kucukarda A., Atci M. M., Secmeler S., Paksoy N., Ferhatoglu F., Ak N., Ayhan M., Ozyukseler D. T., Onder A. H., et al.  
TUMORI JOURNAL, vol.108, no.1, pp.19-25, 2022 (SCI-Expanded)
- XI. **Demonstration of in vivo estrogen receptor status with 16 alpha- [F-18]fluoro-17 beta-oestradiol (FES) PET/CT in a rare case of benign metastasizing leiomyoma**  
Has Simsek D., Kuyumcu S., Ozkan Z. G., Vuralli Bakkaloglu D., Bayram A., Topuz S., Aydiner A., Sanli Y.  
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.48, no.12, pp.4101-4102, 2021 (SCI-Expanded)
- XII. **Nivolumab treatment for metastatic thymic epithelial tumors.**  
Ak N., Aydiner A.  
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, vol.27, pp.1710-1715, 2021 (SCI-Expanded)
- XIII. **Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment**  
Karanlik H., CABIOĞLU N., Oprea A. L., ÖZGÜR İ., AK N., AYDINER A., ÖNDER S., BADEMLER S., GÜLLÜOĞLU M. B.  
BREAST CARE, vol.16, no.5, pp.468-474, 2021 (SCI-Expanded)
- XIV. **Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center**  
Ak N., Toker A., Kara M., Ozkan B., Ulker M., Kaba E., Yegen G., Karaman S., Dagoglu N., Saglam E. K., et al.  
TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, vol.29, no.4, pp.487-495, 2021 (SCI-Expanded)
- XV. **Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy**  
Oner G., Onder S., Karatay H., Ak N., Tukenmez M., Muslumanoglu M., Igci A., Dincceg A., Ozmen V., Aydiner A., et al.  
WORLD JOURNAL OF SURGICAL ONCOLOGY, vol.19, no.1, 2021 (SCI-Expanded)
- XVI. **The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study**  
Ak N., Ozkan B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., Yasar A., SAK S., Tanju S., Dilege S., et al.  
JOURNAL OF BUON, vol.26, no.3, pp.819-829, 2021 (SCI-Expanded)
- XVII. **Long-term outcomes and predictors of recurrence in patients with early-stage node negative breast cancer.**  
Dogan I., Aydin E., Paksoy N., Ferhatoglu F., Ak N., Ibis K., Onder S., Tukenmez M., Cabioglu N., Muslumanoglu M., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded)
- XVIII. **Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.**  
Aydiner A., Dogan I., Khanmammadov N., Saip P., Vatansever S.  
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded)
- XIX. **TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients**

**with locally advanced triple-negative breast cancer**

Cabioglu N., Onder S., Oner G., Karatay H., Tukenmez M., Muslumanoglu M., Igci A., Eralp Y., Aydiner A., Saip P., et al.  
BMC CANCER, vol.21, no.1, 2021 (SCI-Expanded)

- XX. **Sentinel lymph node biopsy alone in locally advanced breast cancer after neoadjuvant chemotherapy: Turkish multicentric neosenti-turk MF-18-02-study**  
Cabioglu N., Karanlik H., Muslumanoglu M., Cakmak G. K., Trablus D. C., Tukenmez M., Ersoy Y. E., URAS C., Zengel B., Emiroglu S., et al.  
CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)
- XXI. **Outcomes of metastatic male breast cancer**  
Dogan I., Khanmammadov N., Aydiner A., Saip P.  
CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)
- XXII. **Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer**  
Dogan I., Aydin E., Khanmammadov N., Aydiner A., Saip P.  
CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)
- XXIII. **Tim3 expression on tumor infiltrating lymphocytes is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple negative breast cancer**  
Cabioglu N., Onder S., Oner G., Karatay H., Tukenmez M., Muslumanoglu M., Igci A., Eralp Y., Aydiner A., Saip P., et al.  
CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)
- XXIV. **GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients**  
Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., ÇİÇİN İ., Basal F. B., et al.  
LUNG CANCER, vol.148, pp.48-54, 2020 (SCI-Expanded)
- XXV. **Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial**  
Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., Bavbek S., Eralp Y., Saip P. M., Guler E. N., et al.  
BALKAN MEDICAL JOURNAL, vol.37, no.2, pp.104-107, 2020 (SCI-Expanded)
- XXVI. **Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy**  
Sari M., Aydiner A.  
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.16, no.1, pp.132-138, 2020 (SCI-Expanded)
- XXVII. **Epidermal growth factor receptor (EGFR) exon 20 mutations in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) naive non-small cell lung carcinoma (NSCLC) and response to erlotinib therapy**  
AYDINER A., Sari M.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- XXVIII. **High expression of pdl-1 in patients with triple negative breast cancer with residual tumor burden after neoadjuvant chemotherapy.**  
Oner G., Önder S., Karatay H., Tükenmez M., Muslumanoglu M., Igci A., Dinccag A., Özmen V., Aydiner A., Yavuz E., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, 2018 (SCI-Expanded)
- XXIX. **Effect of the childhood trauma on the adjustment to cancer in the patients with breast cancer**  
Guveli H., Guveli M. E., Sen F., Oflaz S., Gurdal N., Tambas M., Kucucuk S., Aydiner A., Ozkan M.  
BREAST CANCER, vol.24, no.4, pp.544-551, 2017 (SCI-Expanded)
- XXX. **Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy**  
Sen F., Tambas M., Ozkaya K., Guveli M. E., Ciftci R., Ozkan B., Oral E. N., Saglam E. K., Saip P., Toker A., et al.  
MEDICINE, vol.95, no.30, 2016 (SCI-Expanded)
- XXXI. **Is there any effect of first-day usage of a totally implantable venous access device on complications?**  
Karanlik H., Odabas H., Yildirim I., Ozgur I., Kilic B., Sen F., Kurul S., Aydiner A.

- INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.20, no.6, pp.1057-1062, 2015 (SCI-Expanded)
- XXXII. **Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer Survival and Response to Treatment**  
Aydiner A., Sen F., Tambas M., Ciftci R., Eralp Y., Saip P., Karanlik H., Fayda M., Kucucuk S., Onder S., et al.  
MEDICINE, vol.94, no.52, 2015 (SCI-Expanded)
- XXXIII. **Concomitant Chemoradiotherapy with Etoposide & Cisplatin versus Docetaxel & Cisplatin in Locally Advanced Non-Small Cell Lung Cancer**  
Eralp Y., Sen F., Tambas M., Ozkaya K., Ozkan B., Oral E. N., Saglam E. K., Firat P., Saip P., Toker A., et al.  
JOURNAL OF THORACIC ONCOLOGY, vol.10, no.9, 2015 (SCI-Expanded)
- XXXIV. **Renin-Angiotensin System Blockers May Prolong Survival of Metastatic Non-Small Cell Lung Cancer Patients Receiving Erlotinib**  
Aydiner A., Ciftci R., Sen F.  
MEDICINE, vol.94, no.22, 2015 (SCI-Expanded)
- XXXV. **Effects of Distant Reiki On Pain, Anxiety and Fatigue in Oncology Patients in Turkey: A Pilot Study.**  
DEMIR M., Can G., KELAM A., AYDINER A.  
Asian Pacific journal of cancer prevention : APJCP, vol.16, pp.4859-62, 2015 (SCI-Expanded)
- XXXVI. **A comparison of men and women's experiences of chemotherapy-induced alopecia**  
Can G., Demir M., Erol O., Aydiner A.  
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.17, no.3, pp.255-260, 2013 (SCI-Expanded)
- XXXVII. **Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women**  
Aydiner A.  
BREAST, vol.22, no.2, pp.121-129, 2013 (SCI-Expanded)
- XXXVIII. **Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients**  
Aydiner A., Kilic L., Yildiz I., Keskin S., Sen F., Kucucuk S., Karanlik H., Muslumanoglu M., Igci A.  
MEDICAL ONCOLOGY, vol.30, no.1, 2013 (SCI-Expanded)
- XXXIX. **Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status**  
Aydiner A., Yildiz I., Seyidova A.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.5, pp.3255-3261, 2013 (SCI-Expanded)
- XL. **The efficiency of the acupuncture in prevention of the chemotherapy-induced nausea and vomiting**  
Genc A., Can G., Aydiner A.  
SUPPORTIVE CARE IN CANCER, vol.21, no.1, pp.253-261, 2013 (SCI-Expanded)
- XLI. **Does Beta-blocker Therapy Improve the Survival of Patients with Metastatic Non-small Cell Lung Cancer?**  
Aydiner A., Ciftci R., Karabulut S., Kilic L.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.10, pp.6109-6114, 2013 (SCI-Expanded)
- XLII. **Effects of alopecia on body image and quality of life of Turkish cancer women with or without headscarf**  
Erol O., Can G., Aydiner A.  
SUPPORTIVE CARE IN CANCER, vol.20, no.10, pp.2349-2356, 2012 (SCI-Expanded)
- XLIII. **Association of clinical and pathological variables with survival in thymoma.**  
Aydiner A., Toker A., Sen F., Bicakci E., Saglam E. K., Erus S., Eralp Y., Tas F., Oral E. N., Topuz E., et al.  
Medical oncology (Northwood, London, England), vol.29, no.3, pp.2221-8, 2012 (SCI-Expanded)
- XLIV. **Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity**  
Can G., Aydiner A., Cavdar I.  
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.16, no.3, pp.270-275, 2012 (SCI-Expanded)
- XLV. **The roles of surgery and EMA/CO chemotherapy regimen in primary refractory and non-refractory gestational trophoblastic neoplasia**

- Aydiner A., Keskin S., Berkman S., Bengisu E., Ilhan H. R., Tas F., Topuz E.  
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.138, no.6, pp.971-977, 2012 (SCI-Expanded)
- XLVI. **Complementary and Alternative Therapies Used by Turkish Breast Cancer Patients Undergoing Chemotherapy**  
Can G., Demir M., Aydiner A.  
BREAST CARE, vol.7, no.6, pp.471-475, 2012 (SCI-Expanded)
- XLVII. **Complete Response in a Patient with Granulosa Cell Tumor Treated with a Combination of Leuprolide and Tamoxifen**  
Keskin S., Bengisu E., Tuzlali S., Aydiner A.  
ONKOLOGIE, vol.35, pp.451-453, 2012 (SCI-Expanded)
- XLVIII. **Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study**  
Aydiner A., Sen F., SAGLAM E. K., Oral E. N., Eralp Y., Tas F., Toker A., Dilege S.  
CLINICAL LUNG CANCER, vol.12, no.5, pp.286-292, 2011 (SCI-Expanded)
- XLIX. **Non-pharmacological interventions used by cancer patients during chemotherapy in Turkey**  
Can G., Erol O., Aydiner A., Topuz E.  
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.15, no.2, pp.178-184, 2011 (SCI-Expanded)
- L. **Development and validation of the Nightingale Symptom Assessment Scale (N-SAS) and predictors of the quality of life of the cancer patients in Turkey**  
Can G., Aydiner A.  
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.15, no.1, pp.3-11, 2011 (SCI-Expanded)
- LI. **Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy**  
Akin S., Can G., Aydiner A., Ozdilli K., Durna Z.  
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.14, no.5, pp.400-409, 2010 (SCI-Expanded)
- LII. **The validity and reliability of the Turkish version of the Quality of Life Index [QLI] (Cancer version)**  
Can G., Durna Z., Aydiner A.  
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.14, no.4, pp.316-321, 2010 (SCI-Expanded)
- LIII. **Quality of life and complementary and alternative medicine use among cancer patients in Turkey**  
Can G., Erol O., Aydiner A., Topuz E.  
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.13, no.4, pp.287-294, 2009 (SCI-Expanded)
- LIV. **The role of third generation agents as an induction treatment in concurrent chemoradiotherapy (CRT) for locally-advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials**  
Aydiner A., Can G.  
JOURNAL OF THORACIC ONCOLOGY, vol.4, no.9, 2009 (SCI-Expanded)
- LV. **Detection of Human Papillomavirus DNA by PCR and Southern Blot Hybridization in Colorectal cancer Patients**  
SALEPCI T., YAZICI ÖZBEK H., DANE F., Topuz E., DALAY M. N., ONAT H., AYKAN N. F., SEKER M., AYDINER A.  
JOURNAL OF BUON, vol.14, no.3, pp.495-499, 2009 (SCI-Expanded)
- LVI. **Immune changes in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy**  
Cabioglu N., Müslümanoğlu M. E., Tütüncü Y., Adin-Cinar S., Gürel N., KIRAN B., Ipci A., Özmen V., DAGOGLU T., Aydiner A., et al.  
Turkish Journal of Immunology, vol.13, no.1, pp.15-20, 2008 (SCI-Expanded)
- LVII. **The quality of life and self-efficacy of Turkish breast cancer patients undergoing chemotherapy**  
Akin S., Can G., Durna Z., Aydiner A.  
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.12, no.5, pp.449-456, 2008 (SCI-Expanded)
- LVIII. **Evaluation of the effect of care given by nursing students on oncology patients' satisfaction**  
Can G., Akin S., Aydiner A., Ozdilli K., Durna Z.  
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.12, no.4, pp.387-392, 2008 (SCI-Expanded)

- LIX. **Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer**  
Tas F., Derin D., Guney N., Aydiner A., Topuz E.  
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.4, pp.330-334, 2008 (SCI-Expanded)
- LX. **Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer**  
Tas F., Guney N., Derin D., Camlica H., Aydiner A., Topuz E.  
INVESTIGATIONAL NEW DRUGS, vol.26, no.4, pp.363-368, 2008 (SCI-Expanded)
- LXI. **Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer**  
Aydiner A., Tas F.  
TRIALS, vol.9, 2008 (SCI-Expanded)
- LXII. **Evaluation of sexual function of Turkish women with breast cancer receiving systemic treatment**  
Can G., Oskay U., DURNA Z., Aydiner A., Saip P., Disci R., Kadioglu A.  
ONCOLOGY NURSING FORUM, vol.35, no.3, pp.471-476, 2008 (SCI-Expanded)
- LXIII. **A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer**  
Tas F., Guney N., Derin D., Aydiner A., Topuz E.  
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.2, pp.156-160, 2008 (SCI-Expanded)
- LXIV. **Memenin filloides tümörlerinde tedavi yaklaşımları**  
CABIOĞLU N., ÇELİK O. T., ÖZMEN V., İÇİ A., MÜSLÜMANOĞLU M. E., ÖZÇINAR B., ÖZLÜK M. Y., DURSUN M., DAĞOĞLU T., ASLAY I., et al.  
Meme Sağlığı Dergisi, vol.4, pp.99-104, 2008 (SCI-Expanded)
- LXV. **Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma**  
Tas F., Derin D., Guney N., Camlica H., Aydiner A., Topuz E.  
LUNG CANCER, vol.57, no.1, pp.79-83, 2007 (SCI-Expanded)
- LXVI. **The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer**  
Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., Tas F., Aydiner A., Topuz E.  
MEDICAL ONCOLOGY, vol.24, no.1, pp.39-43, 2007 (SCI-Expanded)
- LXVII. **Increased sister chromatid exchange frequency in young women with breast cancer and in their first-degree relatives.**  
Cefle K., Ucur A., Guney N., Ozturk S., Palanduz S., Tas F., Asoglu O., Bayrak A. G., Muslumanoglu M. E., Aydiner A.  
Cancer genetics and cytogenetics, vol.171, pp.65-7, 2006 (SCI-Expanded)
- LXVIII. **Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma**  
Karagol H., Saip P., Uygun K., Kucucuk S., Aydiner A., Topuz E.  
MEDICAL ONCOLOGY, vol.23, no.4, pp.543-548, 2006 (SCI-Expanded)
- LXIX. **Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer**  
Oral E. N., AYDINER A., ERALP Y., TOPUZ E.  
MEDICAL ONCOLOGY, vol.22, no.4, pp.367-374, 2005 (SCI-Expanded)
- LXX. **Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.**  
TAS F., Yasasever V., DURANYILDIZ D., CAMLICA H., USTUNER Z., AYDINER A., TOPUZ E.  
American journal of clinical oncology, vol.27, no.3, pp.225-8, 2004 (SCI-Expanded)
- LXXI. **Assessment of fatigue in and care needs of Turkish women with breast cancer**  
Can G., Durna Z., Aydiner A.  
CANCER NURSING, vol.27, no.2, pp.153-161, 2004 (SCI-Expanded)
- LXXII. **Inflammatory breast cancer: Results of anthracycline-based neoadjuvant chemotherapy**  
Ozmen V., Cabioglu N., Igci A., Dagoglu T., AYDINER A., Kecer M., Bozfakioglu Y., Dinçer M., Bilir A., Topuz E.  
Breast Journal, vol.9, no.2, pp.79-85, 2003 (SCI-Expanded)

- LXXXIII. **Resectable thymoma: Treatment outcome and prognostic factors in the late adolescent and adult age group**  
ERALP Y., AYDINER A., Kizir A., KAYTAN E., ORAL E., TOPUZ E.  
CANCER INVESTIGATION, vol.21, no.5, pp.737-743, 2003 (SCI-Expanded)
- LXXXIV. **Acetaminophen modulations of chemotherapy efficacy in MDAH 2774 human endometrioid ovarian cancer cells in vitro**  
BILIR A., ALTINOZ M., Attar E., ERKAN M., AYDINER A.  
NEOPLASMA, vol.49, no.1, pp.38-42, 2002 (SCI-Expanded)
- LXXXV. **Thymidine labeling index in epithelial ovarian cancer**  
Salihoglu Y., Bilir A., Aydinler A., ERKAN M., TUZLALI S., ERALP Y.  
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, vol.75, no.2, pp.171-176, 2001 (SCI-Expanded)
- LXXXVI. **Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome**  
Ozmen V., CABIOGLU N., DOLAY K., BILIR A., KECER M., AYDINER A., MUSLUMANOGLU M. E., IGCİ A., BOZFAKIOGLU Y., DAGOGLU T.  
BREAST CANCER RESEARCH AND TREATMENT, vol.68, no.2, pp.147-157, 2001 (SCI-Expanded)
- LXXXVII. **Measurement of serum CA 19-9 may be more valuable than CEA in prediction of recurrence in patients with gastric cancer.**  
TAS F., AYKAN F., AYDINER A., Yasasever V., TOPUZ E.  
American journal of clinical oncology, vol.24, no.2, pp.148-9, 2001 (SCI-Expanded)
- LXXXVIII. **Autophagy and nuclear changes in FM3A breast tumor cells after epirubicin, medroxyprogesterone and tamoxifen treatment in vitro**  
BILIR A., ALTINOZ M., ERKAN M., Ozmen V., AYDINER A.  
PATHOBIOLOGY, vol.69, no.3, pp.120-126, 2001 (SCI-Expanded)
- LXXXIX. **Hypertrophic osteoarthropathy associated with docetaxel treatment.**  
Tas F., Aydinler A., Tenekeci N., Karadeniz A. N., Sakar B., Topuz E.  
Clinical oncology (Royal College of Radiologists (Great Britain)), vol.13, no.2, pp.145-6, 2001 (SCI-Expanded)
- LXXX. **Angiogenesis and p53 protein expression in breast cancer - Prognostic roles and interrelationships**  
TAS F., Yavuz E., AYDINER A., SAİP P., DISCI R., IPLIKCI A., TOPUZ E.  
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.23, no.6, pp.546-553, 2000 (SCI-Expanded)
- LXXXI. **Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.**  
Tas F., Aydinler A., Topuz E., YASASEVER V., Karadeniz A. N., Saip P. M.  
Journal of experimental & clinical cancer research : CR, vol.19, no.4, pp.477-81, 2000 (SCI-Expanded)
- LXXXII. **Multiple primary neoplasms at a single institution: differences between synchronous and metachronous neoplasms.**  
Aydiner A., Karadeniz A. N., Uygun K., Tas S., Tas F., Disci R., Topuz E.  
American journal of clinical oncology, vol.23, no.4, pp.364-70, 2000 (SCI-Expanded)
- LXXXIII. **Celsite (R) port and catheter as an intraperitoneal access device in the treatment of ovarian cancer**  
TOPUZ E., Salihoglu Y., AYDINER A., Saip P. M., TAS F., SOZEN T., BERKMAN S., BENGİSU E.  
JOURNAL OF SURGICAL ONCOLOGY, vol.74, no.3, pp.223-226, 2000 (SCI-Expanded)
- LXXXIV. **Long term results and prognostic factors of granulosa cell tumors of the ovary.**  
SAİP P. M., Uygun K., Topuz E., BAŞARAN M., TAŞ F., AYDINER A., Aslay I., Dincer M.  
ANNALS OF ONCOLOGY, vol.11, pp.87, 2000 (SCI-Expanded)
- LXXXV. **Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer.**  
TOPUZ E., AYDINER A., Saip P. M., ERALP Y., TAS F., Salihoglu Y., TENEKECI N.  
European journal of gynaecological oncology, vol.21, no.6, pp.599-602, 2000 (SCI-Expanded)
- LXXXVI. **The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract.**

- TOPUZ E., ERALP Y., AYDINER A., Saip P. M., TAS F., YAVUZ E., Salihoglu Y.  
ANNALS OF ONCOLOGY, vol.11, pp.87-88, 2000 (SCI-Expanded)
- LXXXVII. **Clinical pharmacokinetic comparative crossover study between three times a day and once a day-oral administration of etoposide**  
AYDINER A., KOYUNCU H., TOPUZ E., Disci R.  
EUROPEAN JOURNAL OF CANCER, vol.35, 1999 (SCI-Expanded)
- LXXXVIII. **Response evaluation of bone metastases in breast cancer: Value of magnetic resonance imaging**  
SAIP P. M., TENEKECI N., AYDINER A., DINCER M., INANC S., DEMIR C., Oral E. N., TOPUZ E.  
CANCER INVESTIGATION, vol.17, no.8, pp.575-580, 1999 (SCI-Expanded)
- LXXXIX. **Prediction of radiological response of bone metastases to therapy by biochemical marker monitoring in patients with breast cancer: A preliminary study**  
SAIP P. M., YASASEVER V., TENEKECI N., AYDINER A., INANC S., ONAT H., Disci R., TOPUZ E.  
JOURNAL OF TUMOR MARKER ONCOLOGY, vol.13, no.3, pp.45-52, 1998 (SCI-Expanded)
- XC. **Catheter complications associated with intraperitoneal chemotherapy**  
TOPUZ E., Saip P. M., AYDINER A., Salihoglu Y., YILMAZ T., TOPUZLU C.  
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.19, no.3, pp.275-279, 1998 (SCI-Expanded)
- XCII. **Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer**  
TOPUZ E., Saip P. M., Aydiner A., Salihoglu Y., BERKMAN S., BENGISU E.  
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.19, no.3, pp.265-270, 1998 (SCI-Expanded)
- XCIII. **The effect of the interval between surgery and radiotherapy on local control and overall survival in patients with breast cancer**  
OZSEKER N., ASLAY I., DINCER M., OZBILEN S., AYDINER A., OZTURK N., CAMLICA H., Disci R., TORE G. G.  
EUROPEAN JOURNAL OF CANCER, vol.33, pp.363, 1997 (SCI-Expanded)
- XCIV. **The effects of different treatment models on Turkish women with uterine sarcoma**  
BERRAK E., ASLAY I., OZTURK N., DINCER M., AYDINER A., OZBILEN S., Disci R., SAIP P. M., TOPUZ E., TORE G. G.  
EUROPEAN JOURNAL OF CANCER, vol.33, pp.943, 1997 (SCI-Expanded)
- XCV. **Intraperitoneal cisplatin - mitoxantrone in ovarian cancer patients with minimal residual disease**  
TOPUZ E., AYDINER A., SAIP P. M., BENGISU E., BERKMAN S., Disci R.  
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.18, no.1, pp.71-75, 1997 (SCI-Expanded)
- XCVI. **ACUTE MYOCARDIAL-INFARCTION IN MAN TREATED WITH EPIRUBICIN FOR NON-HODGKIN-LYMPHOMA**  
AYDINER A., BUGRA Z., TOPUZ E., MERIC M.  
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.18, no.5, pp.444-448, 1995 (SCI-Expanded)
- XCVII. **A comparison of body image, self-esteem and social support in total mastectomy and breast-conserving therapy in Turkish women**  
Alçalar A. N., Aydiner A., Özkan S.  
Supportive Care In Cancer, vol.2, pp.238-241, 1994 (SCI-Expanded)
- XCVIII. **SERUM TUMOR-MARKERS FOR DETECTION OF BONE METASTASIS IN BREAST-CANCER PATIENTS**  
AYDINER A., TOPUZ E., DISCI R., YASASEVER v., DINCER M., DINCOL K., BILGE N.  
ACTA ONCOLOGICA, vol.33, no.2, pp.181-186, 1994 (SCI-Expanded)
- XCVIII. **NEOADJUVANT CHEMOTHERAPY AND RADIOTHERAPY IN LOCALLY ADVANCED UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA**  
Onat H., Altun M., Bilge N., Karadeniz A. N., Erturk N., Aydiner A., Aykan F.  
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol.11, pp.203-206, 1992 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A**

### **Retrospective Cohort Study**

Ak N., Ciftci R., Cabioglu N., Aydiner A.

TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.36, no.2, pp.215-221, 2021 (ESCI)

### **II. Preliminary testing of a Turkish version of the Strategies Used by Patients to Promote Health (SUPPH) Scale in a sample of breast cancer patients**

Akin S., CAN G., Durna Z., AYDINER A.

Journal of Nursing and Healthcare of Chronic Illness, vol.1, no.4, pp.303-310, 2009 (Peer-Reviewed Journal)

### **III. Immune changes in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy.**

CABIOĞLU N., MÜSLÜMANOĞLU M. E., Tütüncü Y., ÇINAR S., Gürel N., Kiran B., İĞCİ A., ÖZMEN V., Dağoğlu T., AYDINER A., et al.

Türk İmmünoloji Dergisi, vol.13, pp.15-20, 2008 (Peer-Reviewed Journal)

### **IV. Clinical usefulness of serum assays of carcinoembryonic antigen and beta 2-microglobulin in the diagnosis and discrimination of metastasis of lung cancer**

Taş F., Aydiner A., Yasasever V., Dişçi R., Topuz E.

Turkish Journal of Cancer, vol.30, pp.148-154, 2000 (Scopus)

## **Books & Book Chapters**

### **I. Jinekolojik Tümörler. Tanı-Tedavi-Takip**

Engin G., Aydiner A. (Editor)

Nobel Tıp Kitapevi, İstanbul, 2017

## **Refereed Congress / Symposium Publications in Proceedings**

### **I. The Contribution of 18 F-FES PET/CT in Therapy Management of Estrogen Receptor Positive Breast Cancer**

Oflas M., Has Şimşek D., Işık E. G., Cabioglu N., İbiş K., Aydiner A., Mudun A., Şanlı Y.

35'th Annual Congress of Nuclear Medicine, Barcelona, Spain, 15 - 19 October 2022

### **II. Outcomes and prognostic factors in patients with HER2-positive metastatic breast cancer with brain metastasis**

Dogan I., Kızıldağ Yırgın İ., Özkurt S., İbiş K., Vatansever S., Saip P. M., Aydiner A.

2022 ASCO Annual Meeting , Illinois, United States Of America, 3 - 07 June 2022, pp.14002

### **III. The Contribution of 18F-FES PET/CT to Therapy Management in Estrogen Receptor Positive Breast Cancer**

Oflas M., Has Şimşek D., Işık E. G., Cabioglu N., İbiş K., Aydiner A., Mudun A., Şanlı Y.

34. Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 27 - 31 March 2022, pp.51

### **IV. Timik Epitelyal Tümörlerde Ga-68 DOTATATE PET/BT Görüntüleme Caner**

Civan C., Özkan Z. G., Özkan B., Işık E. G., Has Şimşek D., Aydiner A., Kara M., Şanlı Y., Kuyumcu S., Toker A.

34. ULUSAL NÜKLEER TIP KONGRESİ , Antalya, Turkey, 27 March - 31 May 2022, pp.16

### **V. EGFR mutasyonlu Metastatik Küçük Hücreli Dışı Akciğer Kanserli Hastalarda Erlotinibin Etkinliğinin Değerlendirilmesi.**

Doğan İ., Paksoy N., Kızıldağ Yırgın İ., Aydiner A.

Ulusal Akciğer Sağlığı Kongresi 2021, Antalya, Turkey, 7 - 10 October 2021, pp.187

### **VI. Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience**

DOĞAN İ., AYDINER E. M., AK N., İBİŞ K., Sukruoglu Ö., Erciyas S., YAZICI H., AYDINER A., SAİP P. M.

ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 November 2020, vol.31

### **VII. Neoadjuvant kemoterapi öncesi biyopsi ile doğrulanmış aksiller metastazı olan hangi hasta grubunda tedavi sonrası aksiller diseksiyon göz ardı edilebilir?**

Karanlık H., Özgür İ., Bademler S., Şen F., Eralp Y., Fayda M., Küçük S., Aydiner A.

20. Ulusal Cerrahi Kongresi, 2016, Antalya, Turkey, 13 - 17 April 2016, pp.1

VIII. **İleri yaş erken evre meme kanserlerinde lokal anestezi altında meme cerrahisi.**

Karanlık H., Özgür İ., Kılıç B., Bademler S., Şen F., Eralp Y., Fayda M., Küçük S., Aydiner A.

13. Ulusal Meme Hastalıkları Kongresi, 2015, Antalya, Turkey, 21 - 25 October 2015, pp.1

IX. **Clinical distinguishing characteristics and management of phyllodes tumors of the breast.**

Tukenmez M., Kulle C. B., Velidedeoglu M., Agcaoglu O., Parlakgul G., Aydoğan F., Onder S., Bozdoğan A., Ozkurt E., Muslumanoglu M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

X. **Factors affecting progression free survival in non-HIV related classical Kaposi sarcoma.**

Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U., Karanlık H., Kurul S., Vatanserver S., Saip P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

XI. **Effect of renin-angiotensin system blockers on survival of metastatic non-small cell lung cancer patients receiving erlotinib.**

Aydiner A., Ciftci R., Sen F.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

XII. **Investigation of mir-15a/mir-16-1 expression levels in B-cell non-Hodgkin lymphomas.**

Yazici H., Kılıç S., avşar M., Sukruoglu O., AKDENİZ D., Ekenel M., Kilic L., Aydiner A., Tuncer B.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

XIII. **Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in lung cancer.**

KARABULUT S., Tastekin D., CİFTÇİ R., Tambas M., DAGOĞLU N., Guveil M. E., Tas F., Duranyıldız D., Aydiner A.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

XIV. **Association of NBS1 expression with improved pathologic complete response rate in HER2-overexpressing breast cancer.**

Sen F., Yavuz E., Yegen G., Karanlık H., Tuzlali S., Aydiner A.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

XV. **Clinicopathological characteristics and survival rate in patients with BRCA1/2 linked ovarian cancer in Turkey**

KESKİN S., EKENEL M., KILIC S., SUKRUOĞLU O., AYDINER A., ERALP Y., TOPUZ E., DALAY N., SAİP P., YAZICI H.

2nd Mediterranean Multidisciplinary Oncology Forum, İstanbul, Turkey, 17 - 19 November 2011

XVI. **Kaposi Sarkomlu Hastalarda E-Cadherin Gen Mutasyonlarının Araştırılması**

TUNÇER Ş. B., ŞEN F., KILIÇ S., KURUL S., AYDINER A., YAZICI H., DALAY M. N.

19.Ulusal Kanser Kongresi, Antalya, Turkey, 21 - 24 April 2011, pp.502

XVII. **HIV-Negatif Kaposi Sarkomlu Hastalarda Serum Human Herpes Virus 8 DNA Pozitiflik Oranı**

ŞEN F., TUNÇER Ş. B., YAZICI H., KURUL S., KARANLIK H., AYDINER A.

19.Ulusal Kanser Kongresi, Antalya, Turkey, 21 - 24 April 2011, pp.311

XVIII. **HIV-Negatif Kaposi Sarkomunda Penis ve Skrotum Tutulumu**

ŞEN F., Yıldız İ., KARANLIK H., TOZ B., TUNÇER Ş. B., Ünal E., AYDINER A.

19.Ulusal Kanser Kongresi, Antalya, Turkey, 21 - 24 April 2011, pp.618

XIX. **Meme kanseri hastalarında yeniden evrelendirme amaçlı PET-BT'nin rolü**

KUYUMCU S., KARAGÖZ F., ŞANLI Y., EKENEL M., YILDIZ İ., KARABULUT S., GEÇER F., IŞIK G., AYDINER A., SAİP P., et

al.

19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.423

- XX. **LOKAL İLERİ MEME KANSERİNDE NEOADJUVAN TEDAVİ AMAÇLI ANTRASİKLİN BAZLI KEMOTERAPİ REJİMİ İLE ANTRASİKLİNE EK OLARAK VERİLEN DOSETAKSELLİ TEDAVİ YÖNTEMLERİNİN KARŞILAŞTIRILMASI**  
Canbay E., Özçınar B., Özmen V., Müslümanoğlu M. E., Eralp Y., Aydiner A., Tuzlah S., İğci A., Dağoğlu T., Kecer M., et al.  
İSTANBUL MEME KANSERİ KONFERANSI VE ULUSAL MEME KANSERİ KONSENSUS TOPLANTISI 2008, İstanbul, Turkey, 21 - 25 October 2008, pp.247
- XXI. **MEMENİN FİLLODES TÜMÖRLERİNDE TEDAVİ YAKLAŞIMLARI**  
Çelik T., Cabioğlu N., Özmen V., İğci A., Müslümanoğlu M. E., Özçınar B., Dağoğlu T., Kecer M., Aslay I., Aydiner A.  
9. ULUSAL MEME HASTALIKLARI KONGRESİ, Ankara, Turkey, 5 - 09 September 2007, pp.47
- XXII. **NEOADJUVAN KEMOTERAPİ SONRASI MEME KORUYUCU CERRAHİDE LOKAL NÜKSÜ ETKİLEYEN FAKTÖRLER: UZUN DÖNEM SONUÇLARIMIZ**  
Cabioğlu N., Özçınar B., Müslümanoğlu M. E., Özmen V., İğci A., Dağoğlu T., Eralp Y., Aslay I., Yavuz E., Tunacı M., et al.  
9. ULUSAL MEME HASTALIKLARI KONGRESİ, Ankara, Turkey, 5 - 09 September 2007, pp.40
- XXIII. **Induction chemotherapy followed by chemoradiotherapy in patients with stage IIIA-B non-small cell lung cancer (NSCLC)**  
DAĞOĞLU SAKİN R. N., AYDINER A., Sakallioğlu B., Oztürk B., Eralp Y., SAİP P. M., ORAL E. N., KİZİR A., Topuz E.  
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.229
- XXIV. **The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer**  
Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., Tas F., Aydiner A., Topuz E.  
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.174
- XXV. **Alteration in cellular immunity in patients with advanced breast cancer after neoadjuvant chemotherapy.**  
Müslümanoğlu M., Cabioğlu N., Deniz G., Tütüncü Y., Çınar S., Polat N. S., İğci A., Aydiner A.  
American Society of Clinical Oncology 34th Annual Meeting , California, United States Of America, 16 - 19 May 1998, pp.618
- XXVI. **Oral etoposide in patients with small cell lung cancer**  
TOPUZ E., TAŞ F., AYDINER A., DEMİR C., SAİP P. M., SALEPÇİ T., KARADENİZ A. N., ERTÜRK N.  
EUROPEAN JOURNAL OF CANCER, Oxford, United Kingdom, 01 September 1997, vol.33, no.8, pp.1072
- XXVII. **Oral etoposide in patients (pts) with Kaposi's sarcoma (KS)**  
AYDINER A., TAS F., SAİP P. M., KARADENİZ A. N., DEMİR C., SALEPÇİ T., TOPUZ E.  
EUROPEAN JOURNAL OF CANCER, Oxford, United Kingdom, 01 September 1997, vol.33, no.8, pp.1178
- XXVIII. **Dimetil sülfoksit ve antineoplastik kombinasyonların FMA3 hücre kültürlerinde koloni oluşumu üzerine etkileri**  
BİLİR A., Özmen V., Müslümanoğlu M., İĞCİ A., bozfakioğlu Y., ASLAY I., ERKAN M., AYDINER A.  
IV. Ulusal Meme Hastalıkları Kongresi, İzmir, Turkey, 1 - 04 March 1997, pp.95
- XXIX. **Adenokistik karsinomda sisplatin, epirubisin, fluorourasil (PEF) kombinasyon kemoterapinin etkinliği**  
İNANÇ S., ONAT H., ALTUN M., AYDINER A., TOPUZ E.  
XI. Ulusal Kanser Kongresi, Antalya, Turkey, 28 May - 02 June 1995, pp.43
- XXX. **Lokal tedavi sonrası rezidiv, lokal nüks ve uzak metastazı olan baş-boyun kanserli hastalarda tek ajanlı kemoterapi sonuçları**  
İNANÇ S., ONAT H., AYDINER A., ÖZTÜRK N., AYKAN F., ALTUN M., KARADENİZ A., DİNÇOL K.  
IV. Kemoterapi Kongresi, Bursa, Turkey, 29 - 31 October 1992, pp.31
- XXXI. **Hodgkin hastalığında Sweet sendromu: bir vak'a takdimi ve literatür özeti**  
ALTUN M., İNANÇ S., ONAT H., BİLGE N., AYDINER A., DARENDELİLER E., OLGAÇ V., KİZİR A.  
XIII. Ulusal Radyoloji Kongresi, İzmir, Turkey, 21 - 23 September 1992

- XXXII. **İntraperitoneal kemoterapi ile tam remisyon sağlanan bir hepatosellüler karsinom olgusu**  
AYDINER A., KIZIR A., ALTUN M., ÖZTÜRK N., TOPUZ E., KARDAŞ H., EMRE A. S.  
XIII. Ulusal Radyoloji Kongresi, İzmir, Turkey, 21 - 23 September 1992
- XXXIII. **Kemik ve sürrenal metastazlı bir hepatosellüler karsinom olgusu**  
KIZIR A., AYKAN F., AYDINER A., ALTUN M., NECATİOĞLU B., ÖZTÜRK N.  
XIII. Ulusal Radyoloji Kongresi, İzmir, Turkey, 21 - 23 September 1992
- XXXIV. **Lokal ileri indiferansiye nazofarenks kanserinde neoadjuvan kemoterapi ve radyoterapi**  
ONAT H., ALTUN M., BİLGE N., KARADENİZ A., ERTÜRK N., ÖZTÜRK N., AYDINER A., AYKAN F.  
IX. Ulusal Kanser Kongresi ve VI. Pediatrik Tümörler Kongresi, İzmir, Turkey, 2 - 07 June 1991, pp.97
- XXXV. **LOKAL İLERİ MEME KANSERİNDE HASTALIKSIZ VE GENEL SAĞKALIMI ETKİLEYEN FAKTÖRLER:  
UZUN DÖNEM SONUÇLARIMIZ**  
Özçınar B., Cabioğlu N., Özmen V., Müslümanoğlu M. E., İğci A., Kecer M., Dağoğlu T., Dınçer M., Eralp Y., Tuzlalı S., et al.  
9. ULUSAL MEME HASTALIKLARI KONGRESİ, Ankara, Turkey, 05 September 2000 - 09 September 2007, pp.68

## Metrics

Publication: 138

Citation (WoS): 871

Citation (Scopus): 987

H-Index (WoS): 15

H-Index (Scopus): 17